{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:15:35Z","timestamp":1792732535923,"version":"4.5.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. In a randomized trial, we tested whether similar improvements would be observed when daratumumab was added to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen. Transplant-ineligible patients with untreated myeloma were randomized to receive VCD or VCD plus daratumumab (VCDD). A total of 121 patients were randomized: 57 in the VCD arm and 64 in the VCDD arm. Baseline characteristics were balanced between the 2 arms. The\u00a0median progression-free survival (PFS) was 16.8\u00a0months (95% confidence interval [CI], 15.3-21.7) and 25.8\u00a0months (95%\u00a0CI, 19.9-33.5) in the VCD and VCDD arms, respectively (hazard ratio, 0.67; log-rank test P\u00a0= .066). In a preplanned analysis, it was demonstrated that the daratumumab-containing arm showed a significant improvement in PFS from 18\u00a0months onward, based on estimates at fixed time points after randomization. The proportions of patients who were progression-free at the following time points were: 18\u00a0months, 48% vs 68% (P\u00a0= .0002); 24\u00a0months, 36% vs 52% (P\u00a0= .0001); and 30\u00a0months, 27% vs 41% (P\u00a0&amp;lt; .0001) in the VCD and VCDD arms, respectively. The best overall response and very good partial response rate were significantly higher in the daratumumab arm compared with the VCD and VCDD arms, respectively (65% vs 86%, P\u00a0= .007; and 28% vs 52%, P\u00a0= .009). Seventy-two percent of the VCDD patients completed the 9 cycles of induction therapy with no grade 3 or 4 peripheral neuropathy adverse events. This study supports VCDD as an option for the initial treatment of transplant-ineligible patients with myeloma. This trial was registered at the Australian New Zealand Clinical Trials Registry (ACTRN12617000202369).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012539","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T18:06:06Z","timestamp":1715623566000},"page":"3721-3730","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-1198","authenticated-orcid":false,"given":"Peter","family":"Mollee","sequence":"first","affiliation":[{"name":"1Haematology Department, Princess Alexandra Hospital, Brisbane, QLD, Australia"},{"name":"2School of Medicine, The University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-8625","authenticated-orcid":false,"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"3Haematology Department, Alfred Hospital, Melbourne, VIC, Australia"},{"name":"4Haematology Department, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojt","family":"Janowski","sequence":"additional","affiliation":[{"name":"5Haematology Department, Calvary Mater Newcastle, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3352","authenticated-orcid":false,"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"6Haematology Department, University of Melbourne and St Vincent\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Campbell","sequence":"additional","affiliation":[{"name":"7Haematology Department, University Hospital Geelong - Barwon Health, Geelong, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gibbs","sequence":"additional","affiliation":[{"name":"8Haematology Department, Eastern Health, Box Hill, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lee","sequence":"additional","affiliation":[{"name":"9Haematology Department, Western Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Lee","sequence":"additional","affiliation":[{"name":"10Haematology Department, Canberra Hospital, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6293-9958","authenticated-orcid":false,"given":"Kerry","family":"Taylor","sequence":"additional","affiliation":[{"name":"11ICON Cancer Centre, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Cochrane","sequence":"additional","affiliation":[{"name":"12Haematology Department, Gold Coast University Hospital and Griffith University, Gold Coast, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Wallington-Gates","sequence":"additional","affiliation":[{"name":"13Haematology Department, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kwok","sequence":"additional","affiliation":[{"name":"14Haematology Department, Westmead Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-2537","authenticated-orcid":false,"given":"Nicholas","family":"Weber","sequence":"additional","affiliation":[{"name":"15Haematology Department, Royal Brisbane and Women\u2019s Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kerridge","sequence":"additional","affiliation":[{"name":"16Haematology Department, Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Weston","sequence":"additional","affiliation":[{"name":"17Haematology Department, Sunshine Coast University Hospital, Sunshine Coast, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-8671","authenticated-orcid":false,"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"18Haematology Department, Royal Prince Alfred Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3204-7500","authenticated-orcid":false,"given":"Michael Francis","family":"Leahy","sequence":"additional","affiliation":[{"name":"19Haematology Department, Royal Perth Hospital, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Horvath","sequence":"additional","affiliation":[{"name":"20Haematology Department, Royal Adelaide Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"3Haematology Department, Alfred Hospital, Melbourne, VIC, Australia"},{"name":"4Haematology Department, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"13","key":"2024072313061546400_bib1","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2024072313061546400_bib2","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2024072313061546400_bib3","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024072313061546400_bib4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10218","key":"2024072313061546400_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"2024072313061546400_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024072313061546400_bib7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024072313061546400_bib8","first-page":"1841","article-title":"Treatment of multiple myeloma and the role of melphalan in the era of modern therapies-current research and clinical approaches","volume":"10","author":"Poczta","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"8","key":"2024072313061546400_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2024072313061546400_bib10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2024072313061546400_bib11","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"23","key":"2024072313061546400_bib12","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2024072313061546400_bib13","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024072313061546400_bib14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41375-018-0339-y","article-title":"Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements","volume":"33","author":"Dejoie","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"2024072313061546400_bib15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2024072313061546400_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"2024072313061546400_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study","volume":"23","author":"Fu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"2024072313061546400_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood-2023-179866","article-title":"GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus\/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years","volume":"142","author":"Mateos","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024072313061546400_bib18","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/10428194.2022.2076847","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study","volume":"63","author":"Yimer","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2024072313061546400_bib20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","article-title":"Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy","volume":"99","author":"Mateos","year":"2014","journal-title":"Haematologica"},{"issue":"16","key":"2024072313061546400_bib21","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"39","key":"2024072313061546400_bib22","doi-asserted-by":"crossref","first-page":"e17147","DOI":"10.1097\/MD.0000000000017147","article-title":"Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China","volume":"98","author":"Yao","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2024072313061546400_bib23","first-page":"56","article-title":"Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma","volume":"9","author":"Ashrafi","year":"2020","journal-title":"J\u00a0Res Pharm Pract"},{"issue":"3","key":"2024072313061546400_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000501791","article-title":"Weekly cyclophosphamide-bortezomib-dexamethasone induction performs comparably to twice-weekly dosing with respect to both response rates and survival after autologous transplant","volume":"143","author":"Thirunavukarasu","year":"2020","journal-title":"Acta Haematol"},{"issue":"1","key":"2024072313061546400_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12288-016-0647-1","article-title":"Once-weekly 1.6\u00a0mg\/m(2) bortezomib BCD regimen in elderly patients with newly diagnosed multiple myeloma who are unfit for standard dose chemotherapy","volume":"33","author":"Tang","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"4","key":"2024072313061546400_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.seminhematol.2017.09.002","article-title":"Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: retrospective evaluation","volume":"55","author":"de Arriba de la Fuente","year":"2018","journal-title":"Semin Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3721\/2235649\/blooda_adv-2023-012539-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3721\/2235649\/blooda_adv-2023-012539-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T13:33:15Z","timestamp":1721741595000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/14\/3721\/516083\/Daratumumab-cyclophosphamide-bortezomib-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012539","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}